期刊文献+

非抗生素类药物在幽门螺杆菌根除中的应用 被引量:4

Application of non-antibiotic drugs in the eradication of Helicobacter pylori
下载PDF
导出
摘要 幽门螺杆菌(Helicobacter pylori,H.pylori)感染是引起胃肠道多种疾病的重要因素。随着抗生素耐药率的逐年上升,H.pylori感染已经成为一个公认的全球健康问题。非抗生素类药物,如益生菌、胃黏膜保护剂、中草药和抗菌肽等的发展对H.pylori的防治提供新思路。本文就非抗生素类药物在H.pylori根除中的应用作一概述。 Helicobacter pylori( H. pylori) is known as an important factor for many gastrointestinal diseases. With the increasing of antibiotic resistance,H. pylori infection is recognized as a worldwide health problem. The development of non-antibiotic drugs,such as probiotics,gastric mucosal protective agent,Chinese herb and antimicrobial peptides,provides a new way of thinking for the prevention of H. pylori. This article was a review for application of non-antibiotic drugs in the eradication of H. pylori.
作者 陈艳 庄则豪
出处 《胃肠病学和肝病学杂志》 CAS 2017年第6期649-652,共4页 Chinese Journal of Gastroenterology and Hepatology
关键词 幽门螺杆菌 非抗生素类药物 根除 Helicobacter pylori Non-antibiotic drugs Eradication
  • 相关文献

参考文献7

二级参考文献108

  • 1张万岱,张秀荣,黄钲华,吴昌信.中药对Hp杀抑作用的筛选试验[J].现代消化及介入诊疗,2001,6(2):55-56. 被引量:14
  • 2曹艳菊,屈昌民,袁群,王社论,梁淑文,杨欣,张文辉.老年人抗生素相关性肠道菌群失调的防治[J].胃肠病学和肝病学杂志,2005,14(2):195-196. 被引量:34
  • 3王绪霖,缴稳玲,吕宗舜,杨恕,陈桂芳.抑制幽门螺旋菌中药的初步筛选[J].中国中西医结合杂志,1994,14(9):534-536. 被引量:351
  • 4马松炎.联合叶酸、胃复春治疗幽门螺杆菌(Hp)阳性胃癌前期病变36例[J].临床和实验医学杂志,2006,5(7):942-943. 被引量:5
  • 5Kuwayama H. Zinc compound is a novel, highly effective triple therapy for eradication of Helicobacter pylori. Gastroenterology 1995; 108: A138.
  • 6Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genetic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-168 .
  • 7Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-728.
  • 8Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-meohenyton 4'-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-154.
  • 9Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626-633.
  • 10Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96: 615-625.

共引文献146

同被引文献56

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部